双表达弥漫大B细胞淋巴瘤(DEL DLBCL)是指淋巴瘤组织免疫组化染色是同时表达MYC(表达比例超过40%)和BCL2(表达比例超过50%)。DEL淋巴瘤约占初发弥漫大B细胞淋巴瘤的25-30%。DEL在细胞来源为ABC亚型中占多数。RCHOP方案治疗后的5年整体生存不超过30%。单独MYC阳性或阴性、单独BCL2阳性或阴性的患者之间的生存没有...
我们在II期临床研究中发现西达本胺联合R-CHOP方案(CR-CHOP)可以显著提升DE-DLBCL的疗效。同时我们也开展了DE-DLBCL的转化医学研究,发现DE-DLBCL潜在的分子异质性,这群患者具有不同的信号通路和免疫微环境特征,但都对表观遗传调控有所应...
DE-DLBCL治疗中,若患者年龄小于60岁,没有严重的基因学缺陷,可考虑予以BTK抑制剂联合R-CHOP方案治疗,但需注意BTK抑制剂不能轻易停药,可能会引发肿瘤进展;西达本胺作用机制不仅涉及细胞凋亡,同时也涉及免疫机制的改变,且在合并病毒感染的患者中...
FL,滤泡型淋巴瘤; DLBCL,弥漫大B细胞淋巴瘤; AML,急性髓细胞白血病; MDS,骨髓增生异常综合征; ALL,急性淋巴细胞白血病; MM,多发性骨髓瘤。 当前TP53/del(17P)药物及适应症 依鲁替尼 (伊布替尼,Ibrutinib): ✦ 至少接受过一种既往治疗的慢性淋巴细胞白血病(CLL)/小淋巴细胞性淋巴瘤(SLL)(有或无染色体17p...
B Introduction: b "Double Expressor Lymphomas" (DEL) refer to high-risk diffuse large B-cell lymphoma (DLBCL) that are positive for MYC and BCL2 by immunohistochemistry (IHC). We recently demonstrated using single-cell resolved analysis that the extent of cells with a unique co-expression ...
Dr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCL Dr Bryce on the Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC Dr Fenske on the Benefit With Auto-HSCT in MRD-Positive Patients With MCL in First CR ...
Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospec... P Mondello,N Steiner,W Willenbacher,... - 《Oncologist》 被引量: 7发表: 2016年 Impact of post-ASCT maintenance therapy on outcomes in ...
The adverse prognosis of R8q24 was observed only in DLBCL while del(13q) and +7q had a similar effect in DLBCL and BL. These results emphasize ... HA Poirel,MS Cairo,NA Heerema,... - 《Leukemia》 被引量: 211发表: 0年 Possible evidence for genomic imprinting in childhood acute myelo...
3. Polatuzumab Vedotin联合苯达莫司汀及利妥昔单抗(pola-BR)对比苯达莫司汀联合利妥昔单抗(BR)治疗复发/难治性DLBCL的疗效分析 [J] . 应志涛 . 循证医学 . 2020,第002期 4. 利妥昔单抗治疗难治性肝脏移植物抗宿主病3例 [J] . 李含 . 重庆医学 . 2017,第005期 5. 戈利木单抗治疗非...
Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCLRelated...